With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans
Executive Summary
Drug Review Profile: Agency reviewed Celltrion's application while also negotiating an initial Pediatric Study Plan, and it crafted an exemption so that Inflectra and other biosimilars will not need to be studied in Crohn's disease patients as young as two years old.
You may also be interested in...
Drug Review Profiles: Behind The Scenes At US FDA
A year in our long-running series of deep dives into FDA review documents.
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.